{
    "clinical_study": {
        "@rank": "1638", 
        "arm_group": [
            {
                "arm_group_label": "Tobacco flavor", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Tobacco Flavor + IV saline, Tobacco Flavor + IV nicotine (0.25 mg/70kg), Tobacco Flavor + IV nicotine (0.5 mg/70kg)"
            }, 
            {
                "arm_group_label": "Low dose menthol", 
                "arm_group_type": "Active Comparator", 
                "description": "Low dose menthol + IV saline, Low dose menthol + IV nicotine (0.25 mg/70kg), Low dose menthol + IV nicotine (0.5 mg/70kg)"
            }, 
            {
                "arm_group_label": "High dose menthol", 
                "arm_group_type": "Active Comparator", 
                "description": "High dose menthol + IV saline, High dose menthol + IV nicotine (0.25 mg/70kg), High dose menthol + IV nicotine (0.5 mg/70kg)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will help determine if menthol administered by inhalation via electronic\n      cigarettes (e-cigarette) changes the reinforcing effects of pure nicotine administered\n      intravenously in cigarette smokers who smoke mentholated or non-mentholated cigarettes."
        }, 
        "brief_title": "The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Nicotine Dependence", 
        "condition_browse": {
            "mesh_term": "Tobacco Use Disorder"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male smokers, aged 18 to 30 years;\n\n          -  History of smoking for the past 12 months, at least one cigarette per day; smoking\n             status is verified      with urinary cotinine levels above 10 ng/ml;\n\n          -  Not seeking treatment for nicotine dependence at the time of study entry;\n\n          -  In good health as verified by medical history, screening examination, and screening\n             laboratory tests;\n\n          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and\n             using acceptable birth control methods.\n\n        Exclusion Criteria:\n\n          -  History of major medical illnesses that the physician investigator deems as\n             contraindicated for the   patient to be in the study\n\n          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or\n             anxiolytics);\n\n          -  A psychiatric diagnosis and / or treatment for Axis I disorders including major\n             depression, bipolar affective disorder, schizophrenia or panic disorder in the past\n             month\n\n          -  Abuse of alcohol or any other recreational or prescription drugs in the past 30 days.\n\n          -  Any allergy to propylene glycol or menthol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "30 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102100", 
            "org_study_id": "1309012678"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tobacco flavor", 
                    "Low dose menthol", 
                    "High dose menthol"
                ], 
                "description": "Subjects in each arm will receive three infusions in a fixed order one hour apart. The first infusion will be saline, the second infusion will be nicotine (.25 mg / 70kg) and the third infusion will be nicotine (0.5 mg / 70 kg).", 
                "intervention_name": "IV nicotine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tobacco flavor", 
                "description": "A popular 'Burly' tobacco flavor used in e-cigarettes will be used as the placebo comparator.", 
                "intervention_name": "Tobacco Flavor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low dose menthol", 
                "description": "A low dose of menthol will be added to the tobacco flavor.", 
                "intervention_name": "Low dose Menthol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose menthol", 
                "description": "A higher dose of menthol added to tobacco flavor will be an active intervention.", 
                "intervention_name": "High Dose Menthol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Menthol", 
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "menthol, electronic cigarette, nicotine, smoking, tobacco", 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lance.barnes@yale.edu", 
                    "last_name": "Lance Barnes", 
                    "phone": "203-937-4823"
                }, 
                "contact_backup": {
                    "email": "katherine.barrett@va.gov", 
                    "last_name": "Kathy Barrett, BS", 
                    "phone": "203-932-5711", 
                    "phone_ext": "5972"
                }, 
                "facility": {
                    "address": {
                        "city": "West Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06516"
                    }, 
                    "name": "VA Connecticut Health Care System"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lance.barnes@yale.edu", 
                    "last_name": "Lance Barnes", 
                    "phone": "203-937-4823"
                }, 
                "facility": {
                    "address": {
                        "city": "West Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06516"
                    }, 
                    "name": "Connecticut VA Healthcare System"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Menthol's Effects on Nicotine Reinforcement in Smokers", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Mehmet Sofuoglu, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The peak change in the intensity of subjective effects as measured by the DEQ will be measured after each intravenous infusion.", 
            "measure": "Peak Change on Items of the Drug Effects Questionnaire (DEQ)", 
            "safety_issue": "No", 
            "time_frame": "up to 55 minutes post-infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102100"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Mehmet Sofuoglu", 
            "investigator_title": "Director of VA New England Mental Illness Research, Education and Clinical Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}